Literature DB >> 8673105

Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle.

K Poetter1, H Jiang, S Hassanzadeh, S R Master, A Chang, M C Dalakas, I Rayment, J R Sellers, L Fananapazir, N D Epstein.   

Abstract

The muscle myosins and hexomeric proteins consisting of two heavy chains and two pairs of light chains, the latter called essential (ELC) and regulatory (RLC). The light chains stabilize the long alpha helical neck of the myosin head. Their function in striated muscle, however, is only partially understood. We report here the identification of distinct missense mutations in a skeletal/ventricular ELC and RLC, each of which are associated with a rare variant of cardiac hypertrophy as well as abnormal skeletal muscle. We show that myosin containing the mutant ELC has abnormal function, map the mutant residues on the three-dimensional structure of myosin and suggest that the mutations disrupt the stretch activation response of the cardiac papillary muscles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673105     DOI: 10.1038/ng0596-63

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  154 in total

1.  Myocyte hypertrophy: the long and winding RhoA'd.

Authors:  T Finkel
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 2.  Molecular genetics of cardiomyopathies.

Authors:  G Shah; R Roberts
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

Review 3.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 4.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

5.  Essential myosin light chain as a target for caspase-3 in failing myocardium.

Authors:  Alessandra Moretti; Hans-Jörg Weig; Thomas Ott; Melchior Seyfarth; Hans-Peter Holthoff; Diana Grewe; Angelika Gillitzer; Lorenz Bott-Flügel; Albert Schömig; Martin Ungerer; Karl-Ludwig Laugwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

6.  Kinetic effects of myosin regulatory light chain phosphorylation on skeletal muscle contraction.

Authors:  Julien S Davis; Colleen L Satorius; Neal D Epstein
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

7.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies.

Authors:  Kenneth R Chien
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 8.  Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy.

Authors:  Sunil Yadav; Danuta Szczesna-Cordary
Journal:  Biophys Rev       Date:  2017-01-25

9.  Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.

Authors:  Ting Shi; Christine S Moravec; Dianne M Perez
Journal:  J Recept Signal Transduct Res       Date:  2013-02-06       Impact factor: 2.092

Review 10.  Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations.

Authors:  Wenrui Huang; Danuta Szczesna-Cordary
Journal:  J Muscle Res Cell Motil       Date:  2015-09-18       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.